Cargando…

Emerging treatment modalities for systemic therapy in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) has long been a major global clinical problem as one of the most common malignant tumours with a high rate of recurrence and mortality. Although potentially curative therapies are available for the early and intermediate stages, the treatment of patients with advanced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qing, Xin, Xu, Wenjing, Zong, Jingjing, Du, Xuanlong, Peng, Hao, Zhang, Yewei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380325/ https://www.ncbi.nlm.nih.gov/pubmed/34419152 http://dx.doi.org/10.1186/s40364-021-00319-3

Ejemplares similares

Multifunctional Nanoplatform Based on Sunitinib for Synergistic Phototherapy and Molecular Targeted Therapy of Hepatocellular Carcinoma
por: Xu, Wenjing, et al.
Publicado: (2023)

pH-Responsive Pluronic F127–Lenvatinib-Encapsulated Halogenated Boron-Dipyrromethene Nanoparticles for Combined Photodynamic Therapy and Chemotherapy of Liver Cancer
por: Zong, Jingjing, et al.
Publicado: (2021)

RAB42 is a Potential Biomarker that Correlates With Immune Infiltration in Hepatocellular Carcinoma
por: Peng, Hao, et al.
Publicado: (2022)

Integrated Analysis of Immunity- and Ferroptosis-Related Biomarker Signatures to Improve the Prognosis Prediction of Hepatocellular Carcinoma
por: Du, Xuanlong, et al.
Publicado: (2020)

Risk factors and predictive nomograms for early death of patients with advanced hepatocellular carcinoma: a large retrospective study based on the SEER database
por: Zhang, Haidong, et al.
Publicado: (2022)

Downregulated liver-elevated long intergenic noncoding RNA (LINC02428) is a tumor suppressor that blocks KDM5B/IGF2BP1 positive feedback loop in hepatocellular carcinoma
por: Du, Xuanlong, et al.
Publicado: (2023)

RAB6B is a potential prognostic marker and correlated with the remolding of tumor immune microenvironment in hepatocellular carcinoma
por: Peng, Hao, et al.
Publicado: (2022)

Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma
por: Zong, Jingjing, et al.
Publicado: (2020)

Nanotechnology strategies for hepatocellular carcinoma diagnosis and treatment
por: Jia, WeiLu, et al.
Publicado: (2022)

Transarterial Therapy: An Evolving Treatment Modality of Hepatocellular Carcinoma
por: Jazieh, Khalid A., et al.
Publicado: (2014)

Risk factors and predictive nomograms for early death of patients with pancreatic cancer liver metastasis: A large cohort study based on the SEER database and Chinese population
por: Zhang, Haidong, et al.
Publicado: (2022)

Photodynamic and Photothermal Therapy of Hepatocellular Carcinoma
por: Fan, Zhe, et al.
Publicado: (2021)

NIR-Triggered and ROS-Boosted Nanoplatform for Enhanced Chemo/PDT/PTT Synergistic Therapy of Sorafenib in Hepatocellular Carcinoma
por: Wang, Chonggao, et al.
Publicado: (2022)

Cellular based treatment modalities for unresectable hepatocellular carcinoma
por: Damiris, Konstantinos, et al.
Publicado: (2021)

Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies
por: Sun, Weijing, et al.
Publicado: (2018)

Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response
por: He, Penghui, et al.
Publicado: (2022)

Comparison of anesthetic effects of dexmedetomidine and tramadol, respectively, combined with propofol in percutaneous microwave coagulation therapy for hepatocellular carcinoma
por: Chu, Chunqin, et al.
Publicado: (2019)

Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy
por: Xu, Wenjing, et al.
Publicado: (2022)

Artificial Intelligent Multi-Modal Point-of-Care System for Predicting Response of Transarterial Chemoembolization in Hepatocellular Carcinoma
por: Sun, Zhongqi, et al.
Publicado: (2021)

Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities
por: da Fonseca, Leonardo Gomes, et al.
Publicado: (2022)

Which treatment modality should we choose for advanced hepatocellular carcinoma?
por: Kim, Do Young
Publicado: (2010)

Prediction of Survival and Analysis of Prognostic Factors for Patients With Combined Hepatocellular Carcinoma and Cholangiocarcinoma: A Population-Based Study
por: Wang, Jitao, et al.
Publicado: (2021)

Emerging therapies in advanced hepatocellular carcinoma
por: Medavaram, Sowmini, et al.
Publicado: (2018)

Emerging Therapies for Hepatocellular Carcinoma (HCC)
por: Chakraborty, Eesha, et al.
Publicado: (2022)

Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities
por: Golabi, Pegah, et al.
Publicado: (2017)

Advanced therapeutic modalities in hepatocellular carcinoma: Novel insights
por: Shokoohian, Bahare, et al.
Publicado: (2021)

Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma
por: Manzar, Gohar Shahwar, et al.
Publicado: (2022)

Attempt to Establish Prognostic Predictive System for Hepatocellular Carcinoma Using Artificial Intelligence for Assistance with Selection of Treatment Modality
por: Hiraoka, Atsushi, et al.
Publicado: (2023)

Emerging Roles of G Protein-Coupled Receptors in Hepatocellular Carcinoma
por: Peng, Wen-Ting, et al.
Publicado: (2018)

The efficacy of stereotactic body radiation therapy on huge hepatocellular carcinoma unsuitable for other local modalities
por: Que, Jenny Y, et al.
Publicado: (2014)

Combined modality therapy in the adjuvant treatment of uterine serous carcinoma
por: Block, Alec M., et al.
Publicado: (2016)

New treatment modalities with vaccine therapy in renal cell carcinoma
por: Sönmez, Mehmet Giray, et al.
Publicado: (2019)

Comparison of External Beam Radiation Therapy Modalities for Hepatocellular Carcinoma With Macrovascular Invasion: A Meta-Analysis and Systematic Review
por: Wu, Guanheng, et al.
Publicado: (2022)

Nanoscale Phytosomes as an Emerging Modality for Cancer Therapy
por: Kadriya, Ahmad, et al.
Publicado: (2023)

Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
por: Llovet, Josep M., et al.
Publicado: (2022)

Current Application of Nanoparticle Drug Delivery Systems to the Treatment of Anaplastic Thyroid Carcinomas
por: Wang, Chonggao, et al.
Publicado: (2023)

Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma
por: Du, Danyu, et al.
Publicado: (2022)

Outcomes After Stereotactic Body Radiation Therapy as a Bridging Modality to Liver Transplantation for Hepatocellular Carcinoma
por: Garg, Rashi, et al.
Publicado: (2020)

Hepatocellular carcinoma: recent advances and emerging medical therapies
por: Ko, Kwan-Lung, et al.
Publicado: (2020)

Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma
por: Tazi, El Mehdi, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_edlbvjjsr8jhismaeo5jp87ru2